Histogenics Corporation To Announce First Quarter 2017 Financial Results on May 11, 2017
April 27, 2017 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal...
Histogenics Corporation to Present at 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
April 24, 2017 16:15 ET
|
Histogenics Corporation
WALTHAM, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Present at Needham & Company’s 16th Annual Healthcare Conference
March 29, 2017 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
March 16, 2017 06:30 ET
|
Histogenics Corporation
‒ NeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 ‒‒ Strong Performance in all Areas of the Business in 2016 ‒‒ Financing Completed in the Third...
Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
March 09, 2017 08:30 ET
|
Histogenics Corporation
– Data demonstrate Histogenics’ Tissue Engineered Cartilage Constructs Exhibit Mechanical Properties Approaching Native Human Cartilage as Early as Three Weeks in Culture and Prior to Implantation...
Histogenics Corporation to Announce 2016 Financial Results on March 16, 2017
March 02, 2017 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal...
Histogenics Corporation to Present at Upcoming Investor Conferences
February 23, 2017 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
January 11, 2017 16:05 ET
|
Histogenics Corporation
– Data demonstrate significant improvement in cartilage quality over first 24 months after treatment, with stabilization and maturation thereafter out to 60 months – – Improvements in cartilage...
Histogenics Corporation Announces Third Quarter 2016 Financial and Operating Results
November 10, 2016 06:30 ET
|
Histogenics Corporation
- NeoCart® Phase 3 Clinical Trial More than 75% Enrolled -- Enrollment On-Track to Complete by End of Second Quarter of 2017 -- Third Quarter Financing Expected to Fund Company to Phase 3 Data --...
Histogenics Corporation to Announce Third Quarter 2016 Financial Results on November 10, 2016
October 27, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal...